|Source||Chimeric/humanized hybrid (mouse/human)|
|Chemical and physical data|
|Molar mass||148251.25 g·mol−1|
Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.
In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme. It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors. Phase I results were presented at ASCO in 2016.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|